Economic consequences for Medicaid of human immunodeficiency virus infection.
Medicaid is currently a major source of financing for health care for those with acquired immunodeficiency syndrome (AIDS) and to a lesser extent, for those with other manifestations of human immunodeficiency virus (HIV) infection. It is likely to become even more important in the future. This article focuses on the structure of Medicaid in the context of the HIV epidemic, covering epidemiological issues, eligibility, service coverage and use, and reimbursement. A simple methodology for estimating HIV-related Medicaid costs under alternative assumptions about the future is also explained.
Baily
M A
MA
Bilheimer
L
L
Wooldridge
J
J
Langwell
K
K
Greenberg
W
W
D000163:Acquired Immunodeficiency Syndrome / Q000191:economics*; D000328:Adult; D014487:Centers for Medicare and Medicaid Services, U.S.; D003365:Costs and Cost Analysis / Q000706:statistics & numerical data; D004196:Disease Outbreaks / Q000191:economics; D015658:HIV Infections / Q000191:economics*; D006801:Humans; D007348:Insurance, Health / Q000706:statistics & numerical data; D008297:Male; D008484:Medicaid / Q000706:statistics & numerical data*; D014481:United States